bioihbjkbjnl/mcl2 huggingface dataset:
Impact Of Digital Photography & Conventional Method On The Accuracy Of Dental Shade Matching In The Esthetic Zone
Condition: Accuracy of Dental Shade Selection in the Aesthetic Zone
Study type: Interventional

Summary: 
      The aim of this study:

      Is to evaluate the accuracy of digital photography in optimizing shade matching when compared
      to conventional method of shade selection.
    

Detailed description: 
      Randomized control trial, 2 groups will be included. Group 1: Color matching using Vita 3D
      master, using modified (USPHS) criteria Group 2: Color matching using digital photography
      using (Photoshop adopt) the assessment will be through a questionnaire for the patient
      satisfaction outcome using Visual analogue scale
    

Intervention name(s): Digital photography using software Photoshop; Vita 3D master shade guide
Intervention type(s): Device; Device
Intervention description(s): When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).
Images are then opened into Photoshop.
The "INFO" panel must be open.
Click on the small eyedropper in the Info panel window and click on ''Lab Color".
Place the mouse over the center of the tooth to be measured for L value.
Click on the "HSB Color" option, which stands for hue, saturation, and brightness.; Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
Other intervention name(s): Conventional shade matching
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Screening
A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis
Condition: Allergic Bronchopulmonary Aspergillosis
MeSH terms: Aspergillosis; Pulmonary Aspergillosis; Aspergillosis, Allergic Bronchopulmonary
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      The study evaluates the addition of itraconazole to glucocorticoids in management of acute
      stages of allergic bronchopulmonary aspergillosis (ABPA). Half of the participants will
      receive glucocorticoids while the other half will receive itraconazole and glucocorticoids
    

Detailed description: 
      The management of allergic bronchopulmonary aspergillosis (ABPA) includes two important
      aspects namely institution of immunosuppressive therapy in the form of glucocorticoids to
      control the immunologic activity, and close monitoring for detection of relapses. Another
      possible target is to use antifungal agents to attenuate the fungal burden secondary to the
      fungal colonization in the airways. Oral corticosteroids are currently the treatment of
      choice for ABPA associated with bronchial asthma. They not only suppress the immune
      hyperfunction but are also anti-inflammatory.

      Itraconazole, an oral triazole with relatively low toxicity, is active against Aspergillus
      spp. in vitro and in vivo. The activity of itraconazole against Aspergillus spp. is more than
      that of ketoconazole. The administration of itraconazole can eliminate Aspergillus in the
      airways and can theoretically reduce the allergic responses in ABPA. We hypothesize that
      itraconazole when given in the acute stages of ABPA will decrease the chances of relapse and
      progression to glucocorticoid-dependent ABPA.
    

Intervention name(s): Itraconazole; Glucocorticoids
Intervention type(s): Drug; Drug
Intervention description(s): Oral itraconazole 200 mg BD for 6 months; Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
Other intervention name(s): Azole; Steroid
Intervention MeSH terms: Itraconazole; Glucocorticoids
Allocation: Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Photobiomodulation Therapy in Patients With Head and Neck Cancer Post-Radiotherapy
Condition: Head and Neck Cancer; Head and Neck Neoplasms; Xerostomia
MeSH terms: Head and Neck Neoplasms; Xerostomia
Study type: Interventional

Summary: 
      Patients with head and neck cancer post-radiotherapy may improve their perceived and amount
      of saliva after a 3-month Photobiomodulation (PBM) therapy focuses on three main salivary
      glands (parotid, submandibular and sublingual glands).
    

Detailed description: 
      The use of PBM therapy in survivors with head and neck cancer may be an effective treatment
      to improve xerostomia and hyposalivation as side effects of radiotherapy. Although there is
      some scientific evidence on its benefits during or after radiotherapy, it is not sufficient
      to establish it as an effective treatment. For these reasons, studies of higher
      methodological quality such as randomized controlled trials, are needed. This study aims to
      demonstrate the benefits of PBM therapy on xerostomia and hyposalivation in survivors with
      head and neck cancer undergone radiotherapy, and whether the effects are maintained after a
      follow-up period.
    

Intervention name(s): Energy density photobiomodulation (7.5); Sham placebo
Intervention type(s): Device; Device
Intervention description(s): A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).; A total of 22 points will be treated (extraoral and intraoral). 2 sessions per week, for 3 months (24 sessions in total).
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Randomized controlled trial
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Quality of Life; Neoplasms; Xerostomia; Low-Level Light Therapy
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
Condition: Neurogenic Bladder
MeSH terms: Urinary Bladder, Neurogenic
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to investigate the use of Botulinum Toxin A as primary therapy
      for children with neurogenic bladder due to spina bifida and compare results with standard
      oral oxybutynin therapy. This study hopes to demonstrate that Botulinum Toxin A can maintain
      or improve bladder storage function without side effects associated with oxybutynin use.
    


Intervention name(s): Oxybutynin; Botulinum Toxin A injection
Intervention type(s): Drug; Drug
Intervention description(s): standard oral therapy; 10 units/kg injected into the detrusor muscle using cystoscopy
Intervention MeSH terms: Oxybutynin; Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: Pediatric
Once-a-day Immunosuppression(CISECON_a_day)
Condition: Chronic Renal Disease
MeSH terms: Renal Insufficiency, Chronic; Kidney Failure, Chronic
Study type: Interventional
Phase: Phase 4

Summary: 
      The objective of this study is to assess the efficacy and safety and Immunosuppressant
      Therapy Barrier Scale (ITBS) of once daily immunosuppressant maintenance therapy in patients
      who had kidney transplantations earlier.
    

Detailed description: 
      This is a 6-month, single-arm, multi-center, open-label, continuous cohort study. 160
      subjects who had kidney transplantations at least 3 months earlier will participate in the
      study. All enrolled subjects will discontinue the existing Tacrolimus preparations for 6
      months from enrollment and be converted to Extended Release Tacrolimus at a biologically
      equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or
      mycophenolate sodium and be treated with Sirolimus and observed.
    

Intervention name(s): advagrf
Intervention type(s): Drug
Intervention description(s): All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.
advagrf+sirolimus one time to eat.
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: once
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
Condition: COPD
Study type: Interventional
Phase: Phase 3

Summary: 
      A Randomized, Double-Blind, Parallel Group, 28-Week Chronic Dosing, Multi-Center Long-term
      Extension Study to Assess the Safety and Efficacy in Japanese Subjects with Moderate to Very
      Severe Chronic Obstructive Pulmonary Disease (COPD) compared with Symbicort® Turbohaler®
    

Detailed description: 
      This is a multicenter, randomized, double-blind, parallel group, chronic dosing,
      active-controlled, 28-week, safety extension of Study PT010006 to assess the safety and
      efficacy of BGF MDI, GFF MDI, BFF MDI, and Symbicort TBH as an active control over a 52-week
      period in Japanese subjects with moderate to very severe COPD who remain symptomatic on
      maintenance treatment with either an ICS and one or more bronchodilator(s) or two or more
      maintenance bronchodilators.
    

Intervention name(s): BGF MDI (PT010); GFF MDI (PT003); BFF MDI (PT009); Symbicort® Turbohaler® Inhalation Powder
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010; Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003; Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009; Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
Other intervention name(s): BGF; GFF; BFF; Symbicort
Intervention MeSH terms: Budesonide, Formoterol Fumarate Drug Combination
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
Condition: Psoriasis
MeSH terms: Psoriasis
Study type: Observational

Summary: 
      This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services'
      (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab
      patient characteristics, treatment patterns, and outcomes.
    

Detailed description: 
      This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services'
      (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab
      patient characteristics, treatment patterns, and outcomes. Psoriasis (PsO) patients
      initiating secukinumab were identified and indexed to the first secukinumab use using the
      most recent data at study initiation (data period: March 1, 2018 to August 31, 2019) and with
      a subsequent data refresh (data period: March 1, 2017 - July 31, 2020).
    

Intervention name(s): Secukinumab
Intervention type(s): Drug
Intervention description(s): Included all the patients treated with secukinumab
Other intervention name(s): Cosentyx
Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        Psoriasis patients treated with Cosentyx (secukinumab)
The Effect of Recruitment Maneuver With Protective Ventilation During Thoracic Surgery
Condition: Mechanical Ventilation Complication; Thoracic Surgery; Inflammation
MeSH terms: Inflammation
Study type: Interventional

Summary: 
      The purpose of this study is to determine if a recruitment maneuver combined with protective
      ventilatory strategy could reduce the pulmonary and systemic inflammatory responses to
      one-lung ventilation during thoracic surgery.
    


Intervention name(s): protective ventilation; Recruitment maneuver combined with protective ventilation
Intervention type(s): Procedure; Procedure
Intervention description(s): low tidal volume and PEEP; Low tidal volume, PEEP and recruitment maneuver
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary purpose: Prevention
Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea
Condition: Irritable Bowel Syndrome With Diarrhea
MeSH terms: Irritable Bowel Syndrome; Syndrome; Diarrhea
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      To evaluate the efficacy and safety of TCM decoction Chang'an I Recipe in the treatment of
      IBS-D. A multicenter, randomized, double-blind, placebo-controlled clinical trial was
      designed. Patients were applied for central random number and were given corresponding
      treatment according to inclusion sequences.The treatment group was administered the Chang'an
      I Recipe, 150ml/bag, 3 times/day; while the control group was administered the placebo,
      150ml/bag, 3 times/day. Both courses of treatment were 8 weeks.
    


Intervention name(s): Chang'an I Recipe; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.; Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
Other intervention name(s): The treatment group; The control group
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Keywords: IBS-D; Chang'an I Recipe; Placebo
Bioequivalence Study of Metformin 1000 mg Tablets Immediate Release (IR) Versus Glucophage® 1000 mg Tablets IR In Healthy Subjects
Condition: Bioequivalence
Study type: Interventional
Phase: Phase 1

Summary: 
      Bioequivalence Study of 2 formulation of metformin (Metformin GEROPHARM vers. Glucophage®
      Merck )
    

Detailed description: 
      Study to evaluate the bioequivalence of orally administered metformin preparations, immediate
      release tablets, 1 000 mg in normal healthy subjects under fasting and fed conditions
    

Intervention name(s): Metformin; Glucophage®; Metformin; Glucophage®
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): First aIntervention Period:
Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition; Second Intervention Period:
Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition; Third Intervention Period:
Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition; Fourth Intervention Period:
Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition
Other intervention name(s): fasting condition; fasting condition; fed condition; fed condition
Intervention MeSH terms: Metformin
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: four-way crossover
Masking: None (Open Label)
Primary purpose: Basic Science
Keywords: AUC; Cmax; Pharmacokinetics; metformin; fed; fasting
Cytokine Profiles in Breast Cancer Patients Undergoing Chemotherapy
Condition: Mammary Neoplasm, Human; Periodontal Diseases; Chemotherapy Effect
MeSH terms: Mammary Neoplasms, Animal; Breast Neoplasms; Periodontal Diseases
Study type: Interventional

Summary: 
      Aim: This study evaluated the effects of non-surgical periodontal therapy (NSPT) on the
      cytokine profile and the correlation to clinical parameters of patients undergoing
      chemotherapy for breast cancer.

      Materials and methods: 40 patients were allocated: periodontitis patients (P) (n=20) and
      breast cancer with periodontitis patients (CAN/P) (n=20). The clinical parameters: probing
      depth (PD), clinical attachment level (CAL), plaque index (PI), Bleeding on probing (BOP) and
      levels of IFN-γ, IL-4, IL-10, TGF-β, IL-17, IL-2, IL-6, IL-1β and TNF-α in gingival
      crevicular fluid (GCF) were evaluated at baseline, 45 and 180 days after therapy.
    

Detailed description: 
      The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under
      local anesthesia. On average, the treatment of the entire oral cavity was completed within
      four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist
      (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices
      (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with
      multilaminated drills.
    

Intervention name(s): Non surgical periodontal Treatment
Intervention type(s): Procedure
Intervention description(s): The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
Other intervention name(s): scaling and root planning (SRP) under local anesthesia.
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Intervention model description: 40 patients were allocated: periodontitis patients (P) (n=20) and breast cancer with periodontitis patients (CAN/P) (n=20). The clinical parameters: probing depth (PD), clinical attachment level (CAL), plaque index (PI), Bleeding of probing (BOP) and levels of IFN-γ, IL-4, IL-10, TGF-β, IL-17, IL-2, IL-6, IL-1β and TNF-α in gingival crevicular fluid (GCF) were evaluated at baseline, 45 and 180 days after therapy.
Masking: None (Open Label)
Primary purpose: Treatment
Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
Condition: Psoriasis
MeSH terms: Psoriasis
Study type: Observational

Summary: 
      This study is health economic analysis of medicinal treatment options for moderate-to-severe
      psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes
      will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for
      moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various
      different sources, including summary of product characteristics (SPCs) and the German S3
      guideline on psoriasis care, health care utilization data and official statistics.

      The study aims to investigate the comparative cost-effectiveness of biologic and conventional
      systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe
      plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled
      (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as
      well as indirect cost will be considered.
    


Intervention name(s): Methotrexate; Cyclosporins; fumaric acid; Acitretin; Infliximab; etanercept; Adalimumab; Ustekinumab
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention MeSH terms: Cyclosporine; Adalimumab; Infliximab; Etanercept; Methotrexate; Ustekinumab; Acitretin; Cyclosporins
Observational model: Other
Time perspective: Retrospective
Sampling method: Probability Sample
Study population: 
        patients with moderate-to-severe psoriasis, who require systemic treatment to adequately
        control the disease
      
Keywords: moderate-to-severe psoriasis; cost utility analysis; cost effectiveness analysis; systemic treatment
Propolis in Reducing Dentin Hypersensitivity
Condition: Dentin Sensitivity
MeSH terms: Dentin Sensitivity; Hypersensitivity
Study type: Interventional

Summary: 
      Objective: This randomized, double-blind, parallel, placebo-controlled clinical trial aims to
      evaluate the effect of propolis with two distinct concentrations (10% and 15%), and the
      impact on volunteers' quality of life.

      Materials and methods: Volunteers meeting the inclusion and exclusion criteria will be
      randomized and allocated into three groups: Group 1- placebo - toothpaste without active
      ingredient, Group 2- toothpaste with 10% propolis and Group 3. - toothpaste with 15%
      propolis. Number of teeth will be used as sample unit, totaling 22 teeth per group.
      Volunteers will receive oral hygiene instruction with guidance to brush their teeth three
      times a day with toothpaste corresponding to the groups in which they will be allocated for
      30 days. The evaluation of dentin hypersensitivity will be performed with three (3)
      evaluation times: baseline (immediately before the beginning of treatment), 15 and 30 days,
      through tactile and evaporative stimuli, using the visual analog scale (VAS). The
      self-reported evaluation of the volunteers will be done through a questionnaire before the
      beginning and after one month with the completion of the research to determine the impact of
      treatment on their quality of life. The data regarding HD in VAS, if present normal
      distribution, will be used Two-way analysis of variance (ANOVA) with Tukey's post hoc for
      comparison between treatments. However, if the data show anormal distribution, Friedman to
      compare the different times in the same group (intra group), and Kruskal Wallis to make the
      comparison between groups (inter group). To evaluate the QEHD ordinal data, Wilcoxon and
      Mann-Whitney tests will be used. Bioestat 5.3 (Belém, Pará, Brazil) will be used, considering
      an alpha level of 5%.
    


Intervention name(s): Propolis 15%; Propolis 10%; Placebo
Intervention type(s): Other; Other; Other
Intervention description(s): oothpaste formulation with 15% propolis.; Toothpaste formulation with 10% propolis.; Formulation of toothpaste without active ingredient.
Intervention MeSH terms: Propolis
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Dentin Desensitizing Agents; Propolis.
Single-port Laparoscopy in Children and Adolescents
Condition: Benign Ovarian Tumors
MeSH terms: Ovarian Neoplasms
Study type: Observational

Summary: 
      To compare the safety evaluation, efficacy evaluation, long-term aesthetics and psychological
      satisfaction of single-port and multiport laparoscopy for children and adolescents with BOT
      in China.
    


Intervention name(s): single-port laparoscopy surgery; multiport laparoscopy surgery
Intervention type(s): Procedure; Procedure
Intervention description(s): The two groups underwent different surgical procedures.; The two groups underwent different surgical procedures.
Observational model: Cohort
Time perspective: Retrospective
Sampling method: Non-Probability Sample
Study population: 
        All patients aged ≤18 years and pathologically diagnosed with BOT were collected from the
        electronic medical records of six gynecological oncology medical centers in Fujian, China
        between January 2019 and January 2023.